Estrella Immunopharma, Inc. (ESLA)
Nasdaq · Healthcare · Biotechnology
$0.44−5.98%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $19.1M
- 52-week range
- $0.431 – $3.15
- 52-week change
- −66.57%
- EPS (trailing)
- −$0.25
Fiscal year to Dec 2025
- Net income
- −$13.1M
- Diluted EPS
- −$0.35
From the company’s annual report on SEC EDGAR.
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Headquarters: EmeryVille, United States · estrellabio.com